Compliance with Primary Malaria Chemoprophylaxis: Is Weekly Prophylaxis Better Than Daily Prophylaxis?

Figures & data

Table 1 Characteristics of Included Studies

Study	Full Period of Prophylaxis Assessed	Is Recall Period Less Than 6 Months?	Drugs for Which Compliance Data are Reported*	Civil (C) or Military (M) Travelers	Country Traveling from	Country Traveling to	Is the Total Number of Travelers with Adverse Events Reported per Drug?	Reviewers Assessment Grade of Quality**
Belderok et al 2013^Citation27	Yes	Yes	M, A	C	Netherlands	Various	Yes	Good
Bellanger et al 2011^Citation43	Yes	Yes	D	M	France	Cote D’ Ivoire	No	Poor
DePetrillo et al 20104^Citation1	Yes	Yes	A	C	USA	Various	Yes	Good
Frickmann et al 2013^Citation23	No	Not applicable	M, A, D	M	Germany	Various	No	Poor
Fujii et al 2007^Citation28	Yes	Not reported	M	M	Japan	East Timor	Yes	Poor
Goodyer et al 2011^Citation37	Yes	Yes	M, A, D	C	UK	Various	Yes	Good
Hoebe et al 1997^Citation33	Yes	Yes	M	C	Netherlands	Various	No***	Good
Hoefnagel et al^Citation20,Citation34	Yes	Yes	M, A, D	C	Netherlands	Various	No	Good
Landman et al 2015^Citation24	No	Not applicable	M, A, D	M	Various	23 African countries	Yes	Poor
Landry et al 2006^Citation31	Yes	Yes	M	C	Switzerland	Various	Yes	Good
Laver et al 2001^Citation20	No	Not applicable	M, D, C	C	Various	Zimbabwe	No	Poor
Lobel et al 2001^Citation21	No	Not applicable	M, D	C	Various	Kenya	Yes	Poor
Matsumura et al 2005^Citation26	Yes	No	M	C	Japan	Various	Yes	Poor
Mavrogordato et al 2012^Citation36	Yes	Not reported	M, A, D	C	Various	Ethiopia	No	Good
Nicosia et al 2008^Citation42	Yes	Not reported	A	C	Italy	Nigeria, Angola, Congo	Yes	Poor
Peragallo et al 2014^Citation29	Yes	Not reported	M	M	Italy	Afghanistan	Yes	Poor
Petersen et al 2000^Citation32	Yes	Yes	M, C	C	Denmark	Various	Yes	Good
Petersen et al 2003^Citation40	Yes	Not reported	A	M	Denmark	Eritrea	Yes	Good
Rodrigues et al 2019^Citation35	Yes	Yes	M, A, D	C	Brazil	Various	Yes	Good
Sanchez et al 2000^Citation22	No	Not applicable	M	M	Brazil	Angola	No	Poor
Saunders et al 2015^Citation25	No	Not applicable	M, D	M	USA	Afghanistan	Yes	Poor
Shady et al 2015^Citation38	Yes	Yes	M, D	C	Kuwait	Various	No	Good
Sonmez et al 2005^Citation39	No	Not applicable	M, D	M	Turkey	Afghanistan	Yes	Poor
Tan et al 2017^Citation30	Yes	No	M, A, D, C	M	USA	Various	No***	Poor

Notes: *M-Mefloquine, A-Atovaquone/proguanil, C-Chloroquine, D-Doxycycline (data for any other groups in these studies using proguanil alone or chloroquine-proguanil combination was not analysed). **Assessment based on a modified NIH quality assessment tool for cross-sectional and cohort studies (Supplementary Material). ***Number of travelers stopping treatment due to adverse events were reported per drug.

Figure 1 PRISMA flow chart of literature search for this review.

Belderok SM, van den Hoek A, Roeffen W, Sauerwein R, Sonder GJB. Adherence to chemoprophylaxis and plasmodium falciparum anti-circumsporozoite seroconversion in a prospective cohort study of Dutch Short-Term Travelers. PLoS One. 2013;8(2):e56863. doi:10.1371/journal.pone.0056863

 Web of Science ®Google Scholar

Bellanger AP, Faucher JF, Robedat P, Schmitt A, Millon L, Hoen B. Malaria outbreak in French troops returning from Cote d’Ivoire. Scand J Infect Dis. 2011;43(3):230–233. doi:10.3109/00365548.2010.538857

 PubMed Web of Science ®Google Scholar

World Health Organization. World Malaria Report 2019. Geneva, Switzerland: WHO; 2020.

 Google Scholar

Frickmann H, Schwarz NG, Holtherm HU, et al. Compliance with antimalarial chemoprophylaxis in German soldiers: a 6-year survey. Infection. 2013;41(2):311–320. doi:10.1007/s15010-013-0411-5

 Web of Science ®Google Scholar

Fujii T, Kaku K, Jelinek T, Kimura M. Malaria and mefloquine prophylaxis use among Japan ground self-defense force personnel deployed in East Timor. J Travel Med. 2007;14(4):226–232. doi:10.1111/j.1708-8305.2007.00122.x

 Web of Science ®Google Scholar

Goodyer L, Rice L, Martin A. Choice of and adherence to prophylactic antimalarials. J Travel Med. 2011;18(4):245–249. doi:10.1111/j.1708-8305.2011.00534.x

 Web of Science ®Google Scholar

Hoebe C, de Munter J, Thijs C. Adverse effects and compliance with mefloquine or proguanil antimalarial chemoprophylaxis. Eur J Clin Pharmacol. 1997;52(4):269–275. doi:10.1007/s002280050288

 Web of Science ®Google Scholar

Laver SM, Wetzels J, Behrens RH. Knowledge of malaria, risk perception, and compliance with prophylaxis and personal and environmental preventive measures in travelers exiting Zimbabwe from Harare and Victoria Falls International airport. J Travel Med. 2001;8(6):298–303. doi:10.2310/7060.2001.23975

 PubMed Web of Science ®Google Scholar

Hoefnagel JGM, Massar K, Hautvast JLA. Non-adherence to malaria prophylaxis: the influence of travel-related and psychosocial factors. J Infect Public Health. 2020;13(4):532–537. doi:10.1016/j.jiph.2019.10.004

 Web of Science ®Google Scholar

Landman KZ, Tan KR, Arguin PM. Adherence to malaria prophylaxis among Peace Corps Volunteers in the Africa region, 2013. Travel Med Infect Dis. 2015;13(1):61–68.

 Web of Science ®Google Scholar

Landry P, Iorillo D, Darioli R, Burnier M, Genton B. Do travelers really take their mefloquine malaria chemoprophylaxis? Estimation of adherence by an electronic pillbox. J Travel Med. 2006;13(1):8–14. doi:10.1111/j.1708-8305.2006.00005.x

 Web of Science ®Google Scholar

Lobel HO, Baker MA, Gras FA, et al. Use of malaria prevention measures by North American and European travelers to East Africa. J Travel Med. 2001;8(4):167–172. doi:10.2310/7060.2001.22206

 Web of Science ®Google Scholar

Matsumura T, Fujii T, Miura T, et al. Questionnaire-based analysis of mefloquine chemoprophylaxis for malaria in a Japanese population. J Infect Chemother. 2005;11(4):196–198. doi:10.1007/s10156-005-0390-2

 Google Scholar

Mavrogordato A, Lever AM. A cluster of Plasmodium vivax malaria in an expedition group to Ethiopia: prophylactic efficacy of atovaquone/proguanil on liver stages of P. vivax. J Infect. 2012;65(3):269–274. doi:10.1016/j.jinf.2012.04.015

 Web of Science ®Google Scholar

Nicosia V, Colombo G, Consentino M, et al. Assessment of acceptability and ease of use of atovaquone/proguanil medication in subjects undergoing malaria prophylaxis. Ther Clin Risk Manag. 2008;4(5):1105–1110. doi:10.2147/TCRM.S3782

 PubMedGoogle Scholar

Peragallo MS, Sarnicola G, Boccolini D, Romi R, Mammana G. Risk assessment and prevention of malaria among Italian troops in Afghanistan, 2002 to 2011. J Travel Med. 2014;21(1):24–32. doi:10.1111/jtm.12046

 Web of Science ®Google Scholar

Petersen E, Ronne T, Ronn A, Bygbjerg I, Larsen SO. Reported side effects to chloroquine, chloroquine plus proguanil, and mefloquine as chemoprophylaxis against malaria in Danish travelers. J Travel Med. 2000;7(2):79–84. doi:10.2310/7060.2000.00026

 Web of Science ®Google Scholar

Petersen E. The safety of atovaquone/proguanil in long-term malaria prophylaxis of nonimmune adults. J Travel Med. 2003;10(SUPPL.1):S13–S15. doi:10.2310/7060.2003.35050

 Google Scholar

Rodrigues KMD, da Costa ABF, Santoro-Lopes G. Adherence to malaria prophylaxis among travelers from a middle-income country. Rev Soc Bras Med Trop. 2019;52. doi:10.1590/0037-8682-0014-2019

 Web of Science ®Google Scholar

Sanchez JL, Bendet I, Grogl M, et al. Malaria in Brazilian military personnel deployed to Angola. J Travel Med. 2000;7(5):275–282. doi:10.2310/7060.2000.00077

 Web of Science ®Google Scholar

Saunders DL, Garges E, Manning JE, et al. Safety, tolerability, and compliance with long-term antimalarial chemoprophylaxis in American Soldiers in Afghanistan. Am J Trop Med Hyg. 2015;93(3):584–590. doi:10.4269/ajtmh.15-0245

 Web of Science ®Google Scholar

Shady I. Determinants of adherence with malaria chemoprophylactic drugs used in a traveler’s health clinic. J Trop Med. 2015;2015:163716. doi:10.1155/2015/163716

 Google Scholar

Sonmez A, Harlak A, Kilic S, et al. The efficacy and tolerability of doxycycline and mefloquine in malaria prophylaxis of the ISAF troops in Afghanistan. J Infect. 2005;51(3):253–258. doi:10.1016/j.jinf.2005.01.014

 Web of Science ®Google Scholar

Tan KR, Henderson SJ, Williamson J, et al. Long term health outcomes among returned peace corps volunteers after malaria prophylaxis, 1995–2014. Travel Med Infect Dis. 2017;17:50–55. doi:10.1016/j.tmaid.2017.05.003

 Web of Science ®Google Scholar